Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.

One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these muscles, dilating the bronchial passages. This action helps alleviate common asthma symptoms such as wheezing, shortness of breath, and chest tightness.

β2-adrenoceptor agonists can be further categorized into short-acting β2-agonists (SABAs) and long-acting β2-agonists (LABAs). SABAs, including drugs like albuterol and terbutaline (Bricanyl), immediately relieve asthma symptoms. They quickly relax the airway muscles during acute episodes, making them essential for emergencies.

In contrast, LABAs, such as salmeterol (Severent) and formoterol (Symbicort), sustain bronchodilation over an extended period. They are typically used as preventive measures for chronic bronchial conditions, helping to maintain open airways and prevent asthma attacks from occurring.

These medications are often administered via metered-dose inhalers or nebulizers. These devices ensure direct and rapid medication delivery to the respiratory tract, maximizing their effectiveness while minimizing systemic exposure.

Despite their significant benefits in managing asthma, β2-agonists may also yield undesired systemic effects due to their stimulatory action on β2-adrenoceptors present in other parts of the body. The most common adverse effect is tremor, which results from stimulating β2-adrenoceptors in skeletal muscles. Other potential side effects include tachycardia (rapid heart rate) and cardiac dysrhythmias (irregular heart rhythms) resulting from β2-adrenoceptors stimulation in the heart. Patients must use these medications under medical supervision and promptly report any adverse effects.

章から 19:

article

Now Playing

19.2 : Antiasthma Drugs: β2-Adrenoceptor Agonists

Lower Respiratory Disorders

82 閲覧数

article

19.1 : 喘息:病因とマネージメント

Lower Respiratory Disorders

98 閲覧数

article

19.3 : 抗喘息薬:メチルキサンチン

Lower Respiratory Disorders

59 閲覧数

article

19.4 : 抗喘息薬:ロイコトリエン修飾薬

Lower Respiratory Disorders

95 閲覧数

article

19.5 : 抗喘息薬:ムスカリン受容体拮抗薬

Lower Respiratory Disorders

59 閲覧数

article

19.6 : 抗喘息薬:吸入コルチコステロイドとグルココルチコイド

Lower Respiratory Disorders

59 閲覧数

article

19.7 : 抗喘息薬:肥満細胞安定剤と抗IgE薬

Lower Respiratory Disorders

76 閲覧数

article

19.8 : COPD:病因と臨床的特徴

Lower Respiratory Disorders

86 閲覧数

article

19.9 : COPD:気管支拡張薬とコルチコステロイドを使用した管理

Lower Respiratory Disorders

54 閲覧数

JoVE Logo

個人情報保護方針

利用規約

一般データ保護規則

研究

教育

JoVEについて

Copyright © 2023 MyJoVE Corporation. All rights reserved